Pick for FDA faces Senate committee

April 6, 2017
Scott Gottlieb, MD ― President Trump’s pick for commissioner of the U.S. Food and Drug Administration (FDA) ― faced the Senate Health, Education, Labor, and Pensions Committee at a confirmation hearing this week and discussed his thoughts about the drug-approval process. Specifically, Dr. Gottlieb indicated that the current process slows down the rate of drug approvals and can be improved without sacrificing safety. Dr. Gottlieb also stated that his first priority as commissioner of the FDA would be to address the U.S. opioid epidemic.

During the hearing, Dr. Gottlieb also answered questions about his financial and advisory ties ― which were listed in Dr. Gottlieb’s conflict of interest notice ― with about 30 medical companies. Dr. Gottlieb indicated that he would work “…with the ethics officials at HHS and FDA to have continued discussions on what additional steps I should take to make sure I’m fully complying with the law if I’m confirmed into this role.”

Dr. Gottlieb, an internist, served as deputy commissioner of the FDA under President George W. Bush. The Committee is expected to vote on Dr. Gottlieb’s appointment after congressional recess.